NCT07302776 2026-04-17
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
Phase 1 Not yet recruiting
Clinical Trials
103 trialsNCT07528417 2026-04-14
MYELO-CAN:ABX
University of Manitoba
Phase 2 Not yet recruiting
NCT07469046 2026-04-13
VAH vs VA in Newly Diagnosed Elderly AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 3 Not yet recruiting
NCT07469592 2026-04-13
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
University of Miami
Phase NA Not yet recruiting
NCT07392970 2026-04-09
Motixafortide for MRD Sensitization in AML
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT07521124 2026-04-09
ABC-Maint
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase NA Not yet recruiting
NCT07516353 2026-04-08
my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
Dana-Farber Cancer Institute
Phase NA Not yet recruiting
NCT07518654 2026-04-08
ThINKK-01
St. Justine's Hospital
Phase 1 Not yet recruiting
NCT07254793 2026-04-07
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
University of Arizona
Phase 1 Not yet recruiting
NCT07511062 2026-04-06
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
Northside Hospital, Inc.
Phase 1 Not yet recruiting
NCT07374029 2026-04-03
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Beth Israel Deaconess Medical Center
Phase 1 Not yet recruiting
NCT07507825 2026-04-02
VHAG
First People's Hospital of Hangzhou
Phase 2 Not yet recruiting
NCT07505160 2026-04-01
Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT07407140 2026-03-25
VAG-3+7-G
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Not yet recruiting
NCT07486479 2026-03-20
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
The First Affiliated Hospital of Soochow University
Phase 3 Not yet recruiting
NCT07486726 2026-03-20
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine
Phase 1/2 Not yet recruiting
NCT07483749 2026-03-19
HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
The Children's Hospital of Zhejiang University School of Medicine
Not yet recruiting
NCT07478991 2026-03-18
VENP-A-QUI
PETHEMA Foundation
Phase 3 Not yet recruiting
NCT06930352 2026-03-13
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07094750 2026-03-13
Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
Fred Hutchinson Cancer Center
Phase NA Not yet recruiting
NCT07471841 2026-03-13
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Hoosier Cancer Research Network
Phase 2 Not yet recruiting
NCT07372885 2026-03-11
GRACE
University of Manchester
Phase 1/2 Not yet recruiting
NCT07463768 2026-03-11
MIVONU
French Innovative Leukemia Organisation
Phase 2 Not yet recruiting
NCT07464951 2026-03-11
CART123
Children's Hospital of Philadelphia
Phase 1 Not yet recruiting
NCT07060001 2026-03-06
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
The Methodist Hospital Research Institute
Phase 2 Not yet recruiting
NCT07053020 2026-03-04
A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT07449286 2026-03-04
IFN-α in Relapse Prevention.
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT05565105 2026-03-03
CD34+ Transplants for Leukemia and Lymphoma
Baptist Health South Florida
Phase 2 Not yet recruiting
NCT07439211 2026-03-03
GAVEL
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07441980 2026-03-02
A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT07432100 2026-02-25
Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia
Tianjin First Central Hospital
Phase 1 Not yet recruiting
NCT07425782 2026-02-23
Venetoclax Combined With Azacitidine for Consolidation Therapy in AML
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT07423104 2026-02-20
A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia
University of Rochester
Phase 2 Not yet recruiting
NCT07420790 2026-02-19
VenDec-AI
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Not yet recruiting
NCT07411586 2026-02-17
Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07407660 2026-02-12
Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax
Peking University People's Hospital
Phase 3 Not yet recruiting
NCT07386392 2026-02-04
HYPNO-RV LAM
University Hospital, Toulouse
Phase NA Not yet recruiting
NCT07370064 2026-01-27
AML CAR-T
Xuzhou Medical University
Phase 1/2 Not yet recruiting
NCT07355335 2026-01-22
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
Massachusetts General Hospital
Phase 1 Not yet recruiting
NCT07347418 2026-01-16
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS
University of Colorado, Denver
Phase 1 Not yet recruiting
NCT07342244 2026-01-15
Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Tongji Hospital
Phase NA Not yet recruiting
NCT07343687 2026-01-15
Clinico-hematological and Coagulation Profiles in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Intensive Induction Chemotherapy .
Assiut University
Not yet recruiting
NCT07338357 2026-01-13
Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML
First Affiliated Hospital of Guangxi Medical University
Phase EARLY_PHASE1 Not yet recruiting
NCT07319793 2026-01-06
Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT
Peking University People's Hospital
Phase NA Not yet recruiting
NCT06345027 2025-12-16
CASEY
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT07249476 2025-12-16
ENKLA-M
Nantes University Hospital
Not yet recruiting
NCT07269067 2025-12-08
DUALFLOW
University Hospital, Bordeaux
Not yet recruiting
NCT07264010 2025-12-04
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
Nanfang Hospital, Southern Medical University
Phase 2/3 Not yet recruiting
NCT07236931 2025-11-19
Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells
Tongji Hospital
Phase NA Not yet recruiting
NCT07233018 2025-11-18
A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Not yet recruiting